203 related articles for article (PubMed ID: 19496531)
1. Safety and immunogenicity of a human and mouse gp100 DNA vaccine in a phase I trial of patients with melanoma.
Yuan J; Ku GY; Gallardo HF; Orlandi F; Manukian G; Rasalan TS; Xu Y; Li H; Vyas S; Mu Z; Chapman PB; Krown SE; Panageas K; Terzulli SL; Old LJ; Houghton AN; Wolchok JD
Cancer Immun; 2009 Jun; 9():5. PubMed ID: 19496531
[TBL] [Abstract][Full Text] [Related]
2. Immunologic response to xenogeneic gp100 DNA in melanoma patients: comparison of particle-mediated epidermal delivery with intramuscular injection.
Ginsberg BA; Gallardo HF; Rasalan TS; Adamow M; Mu Z; Tandon S; Bewkes BB; Roman RA; Chapman PB; Schwartz GK; Carvajal RD; Panageas KS; Terzulli SL; Houghton AN; Yuan JD; Wolchok JD
Clin Cancer Res; 2010 Aug; 16(15):4057-65. PubMed ID: 20647477
[TBL] [Abstract][Full Text] [Related]
3. gp100(209-2M) peptide immunization of human lymphocyte antigen-A2+ stage I-III melanoma patients induces significant increase in antigen-specific effector and long-term memory CD8+ T cells.
Walker EB; Haley D; Miller W; Floyd K; Wisner KP; Sanjuan N; Maecker H; Romero P; Hu HM; Alvord WG; Smith JW; Fox BA; Urba WJ
Clin Cancer Res; 2004 Jan; 10(2):668-80. PubMed ID: 14760090
[TBL] [Abstract][Full Text] [Related]
4. Phase I trial of a melanoma vaccine with gp100(280-288) peptide and tetanus helper peptide in adjuvant: immunologic and clinical outcomes.
Slingluff CL; Yamshchikov G; Neese P; Galavotti H; Eastham S; Engelhard VH; Kittlesen D; Deacon D; Hibbitts S; Grosh WW; Petroni G; Cohen R; Wiernasz C; Patterson JW; Conway BP; Ross WG
Clin Cancer Res; 2001 Oct; 7(10):3012-24. PubMed ID: 11595689
[TBL] [Abstract][Full Text] [Related]
5. Adjuvant immunization of HLA-A2-positive melanoma patients with a modified gp100 peptide induces peptide-specific CD8+ T-cell responses.
Smith JW; Walker EB; Fox BA; Haley D; Wisner KP; Doran T; Fisher B; Justice L; Wood W; Vetto J; Maecker H; Dols A; Meijer S; Hu HM; Romero P; Alvord WG; Urba WJ
J Clin Oncol; 2003 Apr; 21(8):1562-73. PubMed ID: 12697882
[TBL] [Abstract][Full Text] [Related]
6. Peptide vaccination of patients with metastatic melanoma: improved clinical outcome in patients demonstrating effective immunization.
Markovic SN; Suman VJ; Ingle JN; Kaur JS; Pitot HC; Loprinzi CL; Rao RD; Creagan ET; Pittelkow MR; Allred JB; Nevala WK; Celis E
Am J Clin Oncol; 2006 Aug; 29(4):352-60. PubMed ID: 16891861
[TBL] [Abstract][Full Text] [Related]
7. Immunization of patients with melanoma peptide vaccines: immunologic assessment using the ELISPOT assay.
Pass HA; Schwarz SL; Wunderlich JR; Rosenberg SA
Cancer J Sci Am; 1998; 4(5):316-23. PubMed ID: 9815296
[TBL] [Abstract][Full Text] [Related]
8. Immunization of stage IV melanoma patients with Melan-A/MART-1 and gp100 peptides plus IFN-alpha results in the activation of specific CD8(+) T cells and monocyte/dendritic cell precursors.
Di Pucchio T; Pilla L; Capone I; Ferrantini M; Montefiore E; Urbani F; Patuzzo R; Pennacchioli E; Santinami M; Cova A; Sovena G; Arienti F; Lombardo C; Lombardi A; Caporaso P; D'Atri S; Marchetti P; Bonmassar E; Parmiani G; Belardelli F; Rivoltini L
Cancer Res; 2006 May; 66(9):4943-51. PubMed ID: 16651452
[TBL] [Abstract][Full Text] [Related]
9. Enhanced viral and tumor immunity with intranodal injection of canary pox viruses expressing the melanoma antigen, gp100.
Spaner DE; Astsaturov I; Vogel T; Petrella T; Elias I; Burdett-Radoux S; Verma S; Iscoe N; Hamilton P; Berinstein NL
Cancer; 2006 Feb; 106(4):890-9. PubMed ID: 16404742
[TBL] [Abstract][Full Text] [Related]
10. Protective immunization against melanoma by gp100 DNA-HVJ-liposome vaccine.
Zhou WZ; Kaneda Y; Huang S; Morishita R; Hoon D
Gene Ther; 1999 Oct; 6(10):1768-73. PubMed ID: 10516727
[TBL] [Abstract][Full Text] [Related]
11. Induction of circulating tumor-reactive CD8+ T cells after vaccination of melanoma patients with the gp100 209-2M peptide.
Meijer SL; Dols A; Jensen SM; Hu HM; Miller W; Walker E; Romero P; Fox BA; Urba WJ
J Immunother; 2007; 30(5):533-43. PubMed ID: 17589294
[TBL] [Abstract][Full Text] [Related]
12. T-cell clones from melanoma patients immunized against an anchor-modified gp100 peptide display discordant effector phenotypes.
Dudley ME; Ngo LT; Westwood J; Wunderlich JR; Rosenberg SA
Cancer J; 2000; 6(2):69-77. PubMed ID: 11069222
[TBL] [Abstract][Full Text] [Related]
13. MHC-restricted phosphopeptide antigens: preclinical validation and first-in-humans clinical trial in participants with high-risk melanoma.
Engelhard VH; Obeng RC; Cummings KL; Petroni GR; Ambakhutwala AL; Chianese-Bullock KA; Smith KT; Lulu A; Varhegyi N; Smolkin ME; Myers P; Mahoney KE; Shabanowitz J; Buettner N; Hall EH; Haden K; Cobbold M; Hunt DF; Weiss G; Gaughan E; Slingluff CL
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32385144
[TBL] [Abstract][Full Text] [Related]
14. Granulocyte-macrophage-colony-stimulating factor added to a multipeptide vaccine for resected Stage II melanoma.
Weber J; Sondak VK; Scotland R; Phillip R; Wang F; Rubio V; Stuge TB; Groshen SG; Gee C; Jeffery GG; Sian S; Lee PP
Cancer; 2003 Jan; 97(1):186-200. PubMed ID: 12491520
[TBL] [Abstract][Full Text] [Related]
15. Immunologic and clinical outcomes of vaccination with a multiepitope melanoma peptide vaccine plus low-dose interleukin-2 administered either concurrently or on a delayed schedule.
Slingluff CL; Petroni GR; Yamshchikov GV; Hibbitts S; Grosh WW; Chianese-Bullock KA; Bissonette EA; Barnd DL; Deacon DH; Patterson JW; Parekh J; Neese PY; Woodson EM; Wiernasz CJ; Merrill P
J Clin Oncol; 2004 Nov; 22(22):4474-85. PubMed ID: 15542798
[TBL] [Abstract][Full Text] [Related]
16. Phenotype and functional characterization of long-term gp100-specific memory CD8+ T cells in disease-free melanoma patients before and after boosting immunization.
Walker EB; Haley D; Petrausch U; Floyd K; Miller W; Sanjuan N; Alvord G; Fox BA; Urba WJ
Clin Cancer Res; 2008 Aug; 14(16):5270-83. PubMed ID: 18698047
[TBL] [Abstract][Full Text] [Related]
17. HLA-independent heterogeneity of CD8+ T cell responses to MAGE-3, Melan-A/MART-1, gp100, tyrosinase, MC1R, and TRP-2 in vaccine-treated melanoma patients.
Reynolds SR; Celis E; Sette A; Oratz R; Shapiro RL; Johnston D; Fotino M; Bystryn JC
J Immunol; 1998 Dec; 161(12):6970-6. PubMed ID: 9862732
[TBL] [Abstract][Full Text] [Related]
18. Validation of a HLA-A2 tetramer flow cytometric method, IFNgamma real time RT-PCR, and IFNgamma ELISPOT for detection of immunologic response to gp100 and MelanA/MART-1 in melanoma patients.
Xu Y; Theobald V; Sung C; DePalma K; Atwater L; Seiger K; Perricone MA; Richards SM
J Transl Med; 2008 Oct; 6():61. PubMed ID: 18945350
[TBL] [Abstract][Full Text] [Related]
19. MAGE-A1-, MAGE-A10-, and gp100-derived peptides are immunogenic when combined with granulocyte-macrophage colony-stimulating factor and montanide ISA-51 adjuvant and administered as part of a multipeptide vaccine for melanoma.
Chianese-Bullock KA; Pressley J; Garbee C; Hibbitts S; Murphy C; Yamshchikov G; Petroni GR; Bissonette EA; Neese PY; Grosh WW; Merrill P; Fink R; Woodson EM; Wiernasz CJ; Patterson JW; Slingluff CL
J Immunol; 2005 Mar; 174(5):3080-6. PubMed ID: 15728523
[TBL] [Abstract][Full Text] [Related]
20. Characterization of MHC class-I restricted TCRalphabeta+ CD4- CD8- double negative T cells recognizing the gp100 antigen from a melanoma patient after gp100 vaccination.
Voelkl S; Moore TV; Rehli M; Nishimura MI; Mackensen A; Fischer K
Cancer Immunol Immunother; 2009 May; 58(5):709-18. PubMed ID: 18836718
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
